441 related articles for article (PubMed ID: 9399748)
1. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
2. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K
Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
[TBL] [Abstract][Full Text] [Related]
4. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
Lucas LM; Gerrity MS; Anderson T
Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
[TBL] [Abstract][Full Text] [Related]
5. PPIs vs H2RAs for erosive reflux esophagitis.
King VJ
J Fam Pract; 1998 Mar; 46(3):199-200. PubMed ID: 9519012
[No Abstract] [Full Text] [Related]
6. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis.
Ofman JJ; Yamashita BD; Siddique RM; Larson LR; Willian MK
Am J Manag Care; 2000 Aug; 6(8):905-16. PubMed ID: 11186502
[TBL] [Abstract][Full Text] [Related]
7. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition.
Harris RA; Kuppermann M; Richter JE
Am J Med; 1997 Jan; 102(1):78-88. PubMed ID: 9209204
[TBL] [Abstract][Full Text] [Related]
8. "Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.
Habu Y; Maeda K; Kusuda T; Yoshino T; Shio S; Yamazaki M; Hayakumo T; Hayashi K; Watanabe Y; Kawai K
J Gastroenterol; 2005 Nov; 40(11):1029-35. PubMed ID: 16322946
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness analysis for the treatment of non-erosive reflux disease].
Habu Y; Fukui Y; Maruno T; Hisatsune H; Kawai K
Nihon Rinsho; 2007 May; 65(5):951-5. PubMed ID: 17511239
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage.
Spiegel BM; Dulai GS; Lim BS; Mann N; Kanwal F; Gralnek IM
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):988-997. PubMed ID: 16844422
[TBL] [Abstract][Full Text] [Related]
11. Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophageal reflux disease: the value of long-term data collection.
Arguedas MR; Heudebert GR; Klapow JC; Centor RM; Eloubeidi MA; Wilcox CM; Spechler SJ;
Am J Gastroenterol; 2004 Jun; 99(6):1023-8. PubMed ID: 15180720
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
Habu Y; Yoshino T; Shio S; Hayakumo T; Kawai K
Nihon Rinsho; 2004 Aug; 62(8):1504-9. PubMed ID: 15344541
[TBL] [Abstract][Full Text] [Related]
13. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Inadomi JM; McIntyre L; Bernard L; Fendrick AM
Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
[TBL] [Abstract][Full Text] [Related]
14. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
[TBL] [Abstract][Full Text] [Related]
15. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE
Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
[TBL] [Abstract][Full Text] [Related]
16. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
Festen HP; Schenk E; Tan G; Snel P; Nelis F
Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
[TBL] [Abstract][Full Text] [Related]
17. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
Bardhan KD
Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
[TBL] [Abstract][Full Text] [Related]
18. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
Park W; Hicks DM; Khandwala F; Richter JE; Abelson TI; Milstein C; Vaezi MF
Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
[TBL] [Abstract][Full Text] [Related]
19. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage.
Ofman J; Wallace J; Badamgarav E; Chiou CF; Henning J; Laine L
Am J Gastroenterol; 2002 Aug; 97(8):1941-50. PubMed ID: 12190158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
